Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE EFFECT OF NEBIVOLOL ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH MILD HYPERTENSION

https://doi.org/10.20996/1819-6446-2015-11-3-293-296

Full Text:

Abstract

Aim. To study the effects of nebivolol on bone mineral density (BMD) in postmenopausal women with mild hypertension (HT) and osteopenia.

Material and methods. Postmenopausal women (n=56) aged 50-65 years with mild HT фтв osteopenia were included into the randomized controlled study and divided in two groups (28 patients in each). During 12 months patients of the main group received treatment with nebivolol (5-7.5 mg/day) and patients of the control group received treatment with atenolol (12.5-25 mg/day). Clinical and anthropometric examinations, blood pressure measurements, ECG registrations were performed in all patients initially and after 12 months of treatment. Quantitative estimation of BMD was performed by dual energy X-ray absorptiometry with osteodensitometry DELPHI W manufactured by HOLOGIC company (USA) in the lumbar spine (L1-L4), femoral neck and proximal femur in the anterior-posterior projection. In addition, calcium and bone metabolism indices were determined: ionized calcium, total alkaline phosphatase, C-telopeptide of type I collagen (CTX).

Results. Therapy of mild HT with nebivolol during 12 months showed increase in BMD in the spine according to the T-test from -1.7±0.4 SD to -1.4±0.53 SD (p<0.001), while in atenolol group this index decreased from -1.5±0.7 SD to -1.6±0.64 SD (p<0.001). When evaluating T-test of the femoral neck the index changed in the main group from - 1.4±0.44 SD to -1.27±0.5 SD (p=0.015), in the control group - from -1.3±0.64 SD to -1.5±0.65 SD (p=0.0005). In the study group T-test of proximal femur changed from -0.58±0.4 SD to -0.49±0.4 SD (p=0.003), and in the control group - from -0.8±0.84 SD to -0.83±0.93 SD (p=0.3). The dynamics of the BMD due to 12 month therapy in all investigated bone segments distinguished significantly between study and control groups. Nebivolol therapy group showed reduction in CTX level from 0.367±0.16 to 0.294±0.12 ng/ml (p<0.001), whereas the control group showed increase in this parameter from 0.369±0.15 to 0.499±0.18 ng/ml (p<0.001). The dynamics of the CTX levels distinguished significantly between groups (p<0.001).

Conclusion. The study demonstrated the positive effect of nebivolol on BMD, whereas atenolol had no effect on bone mass.

About the Authors

I. L. Tepoyan
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


D. V. Nebieridze
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


I. A. Skripnikova
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. S. Safaryan
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


V. A. Vygodin
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


V. E. Novikov
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


L. M. Murashko
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


References

1. Oganov RG. Epidemiology of arterial hypertension in Russia and the possibility of prevention. Ter Arkchiv 1997; 69 (8): 66-9. Russian (Оганов Р.Г. Эпидемиология арериальной гипертонии в России и возможности профилактики. Тер Архив 1997;69(8): 66-9).

2. Benevolenskaya LI. Osteoporosis problem in modern medicine. Consilium medicum 2004; 2: 96-9. Russian (Беневоленская Л.И. Остеопороз – проблема остеопороза в современной медицине. Consilium medicum 2004; 2: 96-9).

3. Masi L. Epidemiology of osteoporosis. Clin Cases Miner Bone Metab 2008; 5(1): 11-3.

4. UNFPA annual report 2007. Available at: http://www.unfpa.org/sites/default/files/pubpdf/ar07_eng.pdf. Accessed by 25.06.2015

5. Griffith JF, Wang YX, Zhou H, et al. Reduced bone perfusion in osteoporosis: likely causes in an ovariectomy rat model. Radiology 2010;254(3):739-46.

6. Browner W.S., Seeley D.G., Vogt T.V. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet 1991; 338: 335-38.

7. Bonnet N., Gadois C., McCloskey E., et al. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007; 40: 1209-16.

8. Mangrella M., Rossi F., Fici F. Pharmacology of Nebivolol. Pharmacol Res 1998; 38(6); 419-31.

9. Pasco J.A., Henry M.J., Sanders K.M. et al. Betaadrenergic blockers reduce the risk of fracture partly by increasing bone mineral dencity: Geelong Osteoporosis Study. J Bone Miner Res 2004;19: 19-24.

10. Reid I.R., Gamble G.D., Grey A.B., et al. Beta-blockers use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20:613-8.

11. Rejnmark L., Vestergaard P., Kassem M., et al. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 2004; 75: 365-72.

12. Toker A., Gulcan E., Toker S., et al. Nebivolol might be beneficial in osteoporosis treatment: hypothesis. Tropical journal of pharmaceutical research 2009; 8 (2): 181-6.

13. Boydak B., Nalbarrtgil S., Fici F. et al. A Randomised Comparison of the Effects of Nebivolol and Atenolol with and without Chlorthalidone on the Sexual Function of Hypertensive Men. Clin Drug Invest 2005; 25(6): 409-16.

14. Buvaltsev VI, Nebieridze DV, Spasskaya MB et al. Efficacy and safety of nebivolol in hypertensive patients under outpatient practice. Kardiovaskulyarnaya Terapiya i Profilaktika 2003; 2 (1); 9-16. Russian (Бувальцев В.И., Небиеридзе Д.В., Спасская М.Б. и др. Исследование эффективности и безопасности небиволола у больных артериальной гипертонией в условиях поликлинической практики. Кардиоваскулярная Терапия и Профилактика 2003; 2(1); 9-16).

15. Preobrazhenskiy DV. Nebivolol - superselective ß1-blocker of the third generation: clinical pharmacology and experience in the treatment of cardiovascular diseases. Trudnyy Patsient 2008; 6 (4): 8-11. Russian (Преображенский Д.В. Небиволол – суперселективный ß1-адреноблокатор третьего поколения: клиническая фармакология и опыт в лечении сердечно-сосудистых заболеваний. Трудный Пациент 2008;6(4): 8-11).

16. Hansen M.A., Overgaard K., Christiansen C. Spontaneous postmenopausal bone loss in different skeletal areas-followed up for 15 years. J Bone Miner Res 1995;10: 205-10.

17. Harris H., Dawson-Hughes. Rates of change in bone mineral density of the spine, heel, femoral neck, and radius in healthy postmenopausal women. Bone Miner 1992; 17: 87-95.

18. Yang S., Nguyen N.D., Center J.R., et al. Association between beta-blockers use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 2011;48(3): 451-5.

19. Turker S., Karatosum V., Gunai I. Beta-blockers increase bone mineral dencity. Clin Orthop 2006; 443: 73-4.

20. Bonnet N., Gadois C., McCloskey E., et al. Protective effect of beta-blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007; 40: 1209-16.


For citation:


Tepoyan I.L., Nebieridze D.V., Skripnikova I.A., Safaryan A.S., Vygodin V.A., Novikov V.E., Murashko L.M. THE EFFECT OF NEBIVOLOL ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH MILD HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2015;11(3):293-296. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-3-293-296

Views: 370


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)